Clinical Research Directory
Browse clinical research sites, groups, and studies.
Atomoxetine and DAW2022 on OSA Severity
Sponsor: Brigham and Women's Hospital
Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.
Official title: Effect of Atomoxetine and DAW2022 on OSA Severity
Key Details
Gender
All
Age Range
21 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2022-06-01
Completion Date
2026-06-01
Last Updated
2026-03-03
Healthy Volunteers
No
Conditions
Interventions
Placebo oral capsule
Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
Atomoxetine Oral Capsule [Strattera]
Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States